EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Is EQRx an Existential Threat to the Biopharma Industry?
EQRx Gets $500M To Hit the Gas on High-Quality, Low-Cost Drug Model
EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices